Effeicacy and safety of mytoxantrone associated with flag scheme in patients with relapsed or refractory acute leukemia

International Journal of Development Research

Volume: 
07
Article ID: 
8273
6 pages
Research Article

Effeicacy and safety of mytoxantrone associated with flag scheme in patients with relapsed or refractory acute leukemia

Alvarado Ibarra Martha, García Camacho Alinka Socorro, Álvarez Vera José Luis, Ortiz Zepeda Maricela, Mena Zepeda Verónica and López Hernández Manuel

Abstract: 

Objective: The objective of this investigation was determinate the complete remission, overall survival, disease-free survival and toxicity rates in patients with relapsed or refractory acute leukemia who received FLAG plus mitoxantrone (FLAG-MITO) chemotherapy. Patients and Methods: Prospective, experimental, longitudinal, unicentric, single-arm study. Oral fludarabine 30 mg/m2BSA, cytarabine 2000 mg/m2BSA, mitoxantrone 8 mg/m2BSA and granulocyte colony-stimulating factor 300 mg every 12 hours were administrated to patients with relapsed or refractory acute leukemia. Results: Twelve patients were analyzed, complete remission was found in 75%, median disease-free survival was 5 months and median overall survival was 6 months. Hematologic toxicity in 100% of the patients and one death during induction were observed. All patients were admitted to a febrile neutropenia protocol with central venous catheter as main infection site. Conclusion: We believe that the use of FLAG-MITO regimen is an effective and safe treatment, providing a window of remission to consider bone marrow transplantation.

Download PDF: